PGS Publication: PGP000227

Publication Information (EuropePMC)
Title Association of prostate cancer polygenic risk score with number and laterality of tumor cores in active surveillance patients.
PubMed ID 33956350(Europe PMC)
doi 10.1002/pros.24140
Publication Date May 6, 2021
Journal Prostate
Author(s) Xu J, Isaacs WB, Mamawala M, Shi Z, Landis P, Petkewicz J, Wei J, Wang CH, Resurreccion WK, Na R, Bhanji Y, Novakovic K, Walsh PC, Zheng SL, Helfand BT, Pavlovich CP.
Released in PGS Catalog: Aug. 26, 2021

Associated Polygenic Score(s)

Filter PGS by Participant Ancestry
Individuals included in:
G - Source of Variant Associations (GWAS)
D - Score Development/Training
E - PGS Evaluation
List of ancestries includes:
Display options:
Ancestry legend
Multi-ancestry (including European)
Multi-ancestry (excluding European)
African
East Asian
South Asian
Additional Asian Ancestries
European
Greater Middle Eastern
Hispanic or Latin American
Additional Diverse Ancestries
Not Reported

PGS Developed By This Publication

Polygenic Score ID & Name PGS Publication ID (PGP) Reported Trait Mapped Trait(s) (Ontology) Number of Variants Ancestry distribution Scoring File (FTP Link)
PGS000881
(GRS72_PCa)
PGP000227 |
Xu J et al. Prostate (2021)
Prostate cancer prostate carcinoma 72
-
https://ftp.ebi.ac.uk/pub/databases/spot/pgs/scores/PGS000881/ScoringFiles/PGS000881.txt.gz

Performance Metrics

Disclaimer: The performance metrics are displayed as reported by the source studies. It is important to note that metrics are not necessarily comparable with each other. For example, metrics depend on the sample characteristics (described by the PGS Catalog Sample Set [PSS] ID), phenotyping, and statistical modelling. Please refer to the source publication for additional guidance on performance.

PGS Performance
Metric ID (PPM)
Evaluated Score PGS Sample Set ID
(PSS)
Performance Source Trait PGS Effect Sizes
(per SD change)
Classification Metrics Other Metrics Covariates Included in the Model PGS Performance:
Other Relevant Information
PPM002522 PGS000881
(GRS72_PCa)
PSS001140|
European Ancestry|
1,237 individuals
PGP000227 |
Xu J et al. Prostate (2021)
Reported Trait: Number of positive prostate cancer tumour cores at diagnostic biposy OR: 1.23 [1.06, 1.41] Age at diagnosis, study site
PPM002523 PGS000881
(GRS72_PCa)
PSS001140|
European Ancestry|
1,237 individuals
PGP000227 |
Xu J et al. Prostate (2021)
Reported Trait: Number of positive prostate cancer tumour cores at surveillance biposy OR: 1.26 [1.11, 1.44] Age at diagnosis, study site
PPM002524 PGS000881
(GRS72_PCa)
PSS001140|
European Ancestry|
1,237 individuals
PGP000227 |
Xu J et al. Prostate (2021)
Reported Trait: Bilateral positive prostate cancer tumor cores at diagnostic biopsy OR: 1.27 [1.01, 1.61] Age at diagnosis, study site
PPM002525 PGS000881
(GRS72_PCa)
PSS001140|
European Ancestry|
1,237 individuals
PGP000227 |
Xu J et al. Prostate (2021)
Reported Trait: Bilateral positive prostate cancer tumor cores at surveillance biopsy OR: 1.19 [1.04, 1.36] Age at diagnosis, study site

Evaluated Samples

PGS Sample Set ID
(PSS)
Phenotype Definitions and Methods Participant Follow-up Time Sample Numbers Age of Study Participants Sample Ancestry Additional Ancestry Description Cohort(s) Additional Sample/Cohort Information
PSS001140 All individuals were prostate cancer cases undergoing active surveillance. Patients with favourable-risk prostate cancer and low-volume favourable intermediate-risk prostate cancer were enrolled. Favorable‐risk PCa was defined as Gleason grade group (GG) = 1 and prostate‐specific antigen (PSA) < 10 ng/ml. Low‐volume favorable intermediate‐risk in our study was defined as ≤2 positive cores, and only one of the following characteristics: GG ≤ 2 and/or PSA 10–20 ng/ml. At diagnostic biopsy 765 individuals had 1 tumour core, 272 had 2 tumour cores and 152 had ≥3 tumour cores. Of the individuals with 1, 2 or ≥3 positive cores at diagnostic biopsy, 1127 were unilateral and 95 were bilateral. At any surveillance biopsy 408 individuals had 1 tumour core, 297 had 2 tumour cores and 506 had ≥3 tumour cores. Of the individuals with 1, 2 or ≥3 positive cores at any surveillance biopsy, 635 were unilateral and 582 were bilateral. 1,237 individuals,
100.0 % Male samples
Mean = 65.16 years European JHH, NSUHS